PALB2 생식세포 병원성 유전자 변이의 임상적 의의

Clinical Significance of PALB2 Pathogenic Germline Variant

국립암센터 표적치료연구과¹, 한양대학교 의과대학 한양대학교 구리병원 진단검사의학과², 성균관대학교 의과대학 삼성서울병원 진단검사의학과³, 연세대학교 의과대학 진단검사의학교실⁴, 한양대학교 의과대학 예방의학교실⁵, 한양대학교 바이오빅데이터센터⁶, 국립암센터 유방암센터⁷, 국립암센터 암예방검진센터⁸, 국립암센터 중앙암생존자통합지지센터⁹, 국립암센터 암의생명과학과¹⁰, 국립암센터 진단검사의학과¹¹

Min-Chae Kang, R.N.¹, Jong Eun Park, M.D.², Mi-Ae Jang, M.D.³, Dongju Won, M.D.⁴, Boyoung Park, M.D.^5,6, Seeyoun Lee, M.D.⁷, Dong Ock Lee, M.D.⁸, Kum Hei Ryu, M.D.⁸, Yoon-Jung Chang, M.D.⁹, Sun-Young Kong, M.D. ^1,10,11

Targeted Therapy Branch¹, National Cancer Center, Goyang; Department of Laboratory Medicine², Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri; Department of Laboratory Medicine and Genetics³, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Department of Laboratory Medicine⁴, Yonsei University College of Medicine, Seoul; Department of Preventive Medicine⁵, Hanyang University College of Medicine, Seoul; Bio-BigData Center⁶, Hanyang University, Seoul; Center for Breast Cancer⁷, National Cancer Center, Goyang; Center for Cancer Prevention and Detection⁸, National Cancer Center, Goyang; National Cancer Survivorship Center⁹, National Cancer Center, Goyang; Cancer Biomedical Science¹⁰, National Cancer Center, Goyang; Department of Laboratory Medicine¹¹, National Cancer Center, Goyang, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.